Website glitches

Posted on February 26, 2022 by Pete

Updates to WordPress weren’t working properly with the theme that I was using for DrugWarrant, and we were losing some functionality (along with images, etc.). So I have switched to another theme. It will take a bit of getting used to, and I’m sure there will be glitches that need to be addressed. Please let me know of any problems you see. Thanks for your patience.

This entry was posted in Uncategorized. Bookmark the permalink.

3 Responses to Website glitches

  1. Son of Sam Walton says:
    February 27, 2022 at 4:51 pm

    Speaking of glitches, did our big banks help Putin weather the storm of Sanctions with billions laundered and invested in ways to double that money and play in commodities to stockpile goods since stock market amateurs tend to accidentally buy a tanker of Natural Gas sitting at a Chicago Railroad yard with the folks at the Station telling you to move it now lest you start paying the parking and storage fees–yet they thought it was all on paper.

    Like the Cartels and Terrorists, Russia has hundreds if not thousands of small investment accounts around the world that cannot be touched by sanctions, but generate and protect revenue for them in areas they can use money. Plus cryptocurrency can protect Russian assets and blockchain can help navigate existing pools of money floating around, unrecognized, to re-organized Decentralized Autonomous Organizations and play inside the web for anything that collects revenue, like e-contracts and interest collecting crypto-to-tangible/NTF accounts with a mixture of existing crypto blockchain markets and more corrected–stabilized Russian Version of Crypto–blockchain markets and DAOs who can dip fingers into private equity and unicorns and pre-SPAC ejaculations. And they can sell more drugs and go further with China.

  2. Servetus says:
    March 20, 2022 at 9:56 pm

    A small medical study funded by the National Institute on Drug Abuse (NIDA), titled Risks and Benefits of Obtaining a Medical Marijuana Card in Adults with Pain, Insomnia, or Affective Symptoms: A Randomized Clinical Trial, appears intent on disrupting the marijuana anti-depressant market advantage in favor of promoting Pfizer’s anti-depressants and the mainstream medical profession. Published in the JAMA Network Open and in an AAAS public news release:

    Researchers found that individuals at greatest risk of developing the addictive symptoms of CUD [cannabis use disorder] were those seeking relief from anxiety and depression, suggesting the need for stronger safeguards over the dispensing, use, and professional follow-up of people who legally obtain cannabis through MMCs [medical marijuana cards]. […]

    The team found that the odds of developing CUD were nearly two times higher in the MMC cohort than in the wait list control group, and that by week 12, 10 percent of the MMC group had developed a CUD diagnosis, with the number rising to 20 percent in those seeking a card for anxiety or depression.

    “Our study underscores the need for better decision-making about whether to begin to use cannabis for specific medical complaints, particularly mood and anxiety disorders, which are associated with an increased risk of cannabis use disorder,” says Gilman. Regardless of the specific health condition for which cannabis is sought, Gilman believes that regulation and distribution of cannabis to people with medical marijuana cards must be greatly improved. “There needs to be better guidance to patients around a system that currently allows them to choose their own products, decide their own dosing, and often receive no professional follow-up care.” […]

    The study comes with the following COI [conflict of interest] statement:

    AEE has served as a consultant to Charles River Analytics (NIDA SBIR grant) and Karuna Pharmaceuticals (Chair Data Monitoring Board). GNP has equity holdings in Pfizer Inc. Other investigators report no potential conflicts.

    Charles River Analytics is a company that among many other things writes artificial intelligence software for the healthcare industry that’s used in “medical training and patient assessment”.

    A reduction to absurdity interpretation of this study is that Big Pharma and the general medical industry believe eliminating medical marijuana cards (MMCs) is going to eliminate CUDs. What they appear to be trying to achieve is a money grab that involves taking over the existing MMC business.

    Another problem is that the government provided the tax payer funding for this study, grant number 5R01DA042043 from the National Institute on Drug Abuse, an investigation designed to only benefit the established medical industry and decidedly not medical patients. It concludes that “There were no observed benefits of obtaining a medical marijuana card for pain, anxiety, or depressive symptoms”. No doubt they didn’t look for any.

    The funding makes a government agency, the NIDA, a partner to corporations as well as being a captured federal agency of Big Pharma. Political scientists often interpret such partnerships between the state and the business sector as a form of economic fascism.

  3. darkcycle says:
    March 22, 2022 at 11:53 am

    Good grief. Read that….so clearly a contrived study. This smells like Nora’s been rubbing her ….uh…. nasty bits all over it. There are various motivations in operation when looking at who actually SEEKS OUT a medical card. While many are medicating a diagnosed illness, many others suffering that same illness may still be undiagnosed. They still get relief from their symptoms even though no doctor has “validated” it’s existence with a diagnosis. On top of that, another common motivator is an existing case of “CUD”….we all know pot heads who ran out to shop a doctor to recommend it simply to have access to medical dispensaries and protection from arrest. That is partially down to it’s illegal status. But that won’t get any acknowledgement. Another unacknowledged reality is the fact that of all the addictions, the impacts of Cannabis Use Disorders are most negligible. It is far less damaging than other “Use disorders”. Caffeine addiction is arguably a more dangerous use disorder, and tobacco addiction is levels of magnitude more devastating to health and expected lifespan…yet both of those substances, as well as drugs like dextramethoropham and diphenhydramine are available in ordinary stores with very few restrictions. To arbitrarily restrict access based on the argument that CUD is somehow especially dangerous is laughable. To prohibit it completely and subject people to arrest for possessing as little as a single seed is draconian and extreme. NIDA.
    And it goes almost without saying that “no doubt they did not look for any”. Thank you Servetus. Hope you’re re well and happy in these dangerous, tumultuous times.

Comments are closed.